Bispecific antibodies are moving to earlier lines of treatment

Bispecific antibodies, like other treatments initially approved for later lines of therapy, are moving "upstream" in multiple myeloma treatment, Adams said. She discussed the MajesTEC-3 trial that led to the approval of teclistamab plus daratumumab as second-line therapy, the IMMUNOPLANT trial of linvoseltamab, and the MajesTEC-7 trial comparing a combination of teclistamab, daratumumab and lenalidomide with a combination of talquetamab, daratumumab and lenalidomide.